Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other drugmakers.

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

President Donald Trump took on Big Pharma Monday with an executive order that will reduce the prices for prescriptions. The

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to let compounding

Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?

The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

The pharmaceutical industry, which is well known for its well-resourced lobbying campaigns, has a lesser-known tactic for influencing policy: bankrolling ostensibly independent nonprofit organizations to push industry talking points in Washington and across the nation.